CONTINUING TREATMENT FOR SUBJECTS WHO HAVE PARTICIPATED IN A PRIOR PROTOCOL INVESTIGATING ELOTUZUMAB (CONTINUATION PHASE 2 ROLL-OVER PROTOCOL)

Registry ID

CA204-185

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

BRISTOL-MYERS SQUIBB CANADA

Start date

2016-09-19

Last update

2016-06-07

Conditions

• UNSPECIFIED

Related clinical trials

• AN OBSERVATIONAL, OPEN-LABEL, NON-RANDOMIZED STUDY TO MONTIOR FOR ADVERSE DRUG REACTIONS AMONG PATIENTS ADMINISTERED FEDORAK-MANUFACTURED [F-18]-FDG INJECTION
• INVESTIGATOR-INITIATED PHASE II STUDY OF PEMBROLIZUMAB IMMUNOLOGICAL RESPONSE EVALUATION (INSPIRE)
• EXPLORING THE EFFECTS OF PRAZOSIN ON BASAL DOPAMINE IN HEALTHY HUMANS: A [11C]-(+)-PHNO PET STUDY
• COMPARISON OF MAO-A VT BETWEEN HEALTHY MEN AND WOMEN MEASURED WITH [11C]-HARMINE PET

View on source registry